You are here

Our science / Clinical Trials / Find a Trial / NCT00383253

Methods Study to Characterize Early Indicators of Weight Loss in People

Back to Search Print Save as PDF Bookmark Trial

NCT00383253

Last updated on October 4, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Adelaide, South Australia, 5000 Australia
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects >=18 years of age with BMI >= 30 and

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Females, those with illnesses expected to cause weight loss, those without stable body
weight within 3 months of screening.

NCT00383253
Pfizer
Completed
Methods Study to Characterize Early Indicators of Weight Loss in People

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Obesity
Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones
NCT00576589
All Genders
18+
Years
Multiple Sites
Obesity
Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
NCT00472836
All Genders
18+
Years
Multiple Sites
Morbid Obesity, Metabolic Disease
Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome
NCT00283374
All Genders
18+
Years
Multiple Sites
Obesity
Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
NCT00376285
All Genders
Methods Study to Characterize Early Indicators of Weight Loss in People
A Randomized, Open-Label, Parallel Group, Fixed Energy Deficit Methodology Trial to Characterize Early Efficacy Biomarkers During Treatment of Obesity in Adult, Obese, Male Subjects.
Methods study to characterize early indicators of weight loss in people.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Obesity
  • Behavioral: caloric restriction - 10%
    Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
  • Behavioral: caloric restriction - 25%
    Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
  • Behavioral: caloric restriction - 50%
    Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
  • Behavioral: caloric restriction - Control
    Subjects maintained on their baseline caloric intake (caloric restriction = none)
  • Experimental: 10%
    Intervention: Behavioral: caloric restriction - 10%
  • Experimental: 25%
    Intervention: Behavioral: caloric restriction - 25%
  • Experimental: 50%
    Intervention: Behavioral: caloric restriction - 50%
  • Placebo Comparator: Control
    Intervention: Behavioral: caloric restriction - Control
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
57
March 2008
Not Provided

Inclusion Criteria:

  • Subjects >=18 years of age with BMI >= 30 and < 40 kg/m2

Exclusion Criteria:

  • Females, those with illnesses expected to cause weight loss, those without stable body weight within 3 months of screening.
Sexes Eligible for Study: Male
18 Years to 55 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Australia
 
 
NCT00383253
A9001342
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
  • University of Adelaide
  • Royal Adelaide Hospital
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now